Carles Galdeano
Institut Barcelona d'Estudis Internacionals(ES)Institut Botànic de Barcelona(ES)Institute for Research in Biomedicine(ES)Instituto de Química y Fisicoquímica Biológicas(AR)Institut de Biomedicina de la Universitat de BarcelonaUniversitat de Barcelona(ES)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Cholinesterase and Neurodegenerative Diseases, Ubiquitin and proteasome pathways, Computational Drug Discovery Methods, Eicosanoids and Hypertension Pharmacology
Most-Cited Works
- → Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities(2014)396 cited
- → Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition(2016)234 cited
- → Novel Donepezil-Based Inhibitors of Acetyl- and Butyrylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation(2008)202 cited
- → Pyrano[3,2-c]quinoline−6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds(2009)169 cited
- → Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298)(2017)158 cited